MRK Stock (Merck & Co.): $65B Revenue, 1% Growth

Merck has the feel of an old-school pharmaceutical powerhouse leaning into a modern scramble to replace its crown jewel. Merck ($MRK) pairs blockbuster medicines and a steady animal-health business with heavy R&D and strategic acquisitions meant to seed future growth. But the story tense is built around Keytruda: its main patent cliff in 2028 forces a race to deliver hits from a pipeline of more than 20 potential launches. Can this seasoned giant engineer a successful handoff before the revenue cliff hits?This podcast is for informational and educational purposes only. Information may not be complete or accurate. It does not constitute financial, investment, legal, or other professional advice. Always do your own research and consult with a licensed financial advisor.And don't forget, you can suggest the tickers you're interested in at www.the5minuteticker.com.